


**Fig. S1:** Viability tests to determine the $IC_{50}$ value of various mTOR inhibitors in neuroblastoma cell line (A) Kelly and (B) IMR-32 after 72h treatment. The cell viability was tested by applying the MTT test as described under Methods.




**Fig. S2:** Viability tests to determine $IC_{50}$ of Rapamycin and Torin-2 in neuroblastoma cell line (A) Kelly, (B) IMR-32, and (C) SK-N-BE(2) after 72h treatment. The cell viability was tested by applying the MTT test as described under Methods.




**Fig. S3:** Viability tests to determine $IC_{50}$ of Dasatinib in neuroblastoma cell line (A) Kelly, (B) IMR-32, and (C) SK-N-BE(2) after 72h treatment. The cell viability was tested by applying the MTT test as described under Methods.

**Table S1:** Viability tests to determine $IC_{50}$ of Dasatinib in neuroblastoma (NB) cell line Kelly, IMR-32, and SK-N-BE(2).

| NB cell line | Dasatinib [μM] |
|---|---|
| **Kelly** | 9.47 ± 0.010 |
| **IMR-32** | 1.53 ± 0.053 |
| **SK-N-BE(2)** | 25.73 ± 0.003 |

**Table S2:** Viability tests to determine the dose reduction factor (DRF) of Dasatinib combined with Rapamycin in neuroblastoma (NB) cell line Kelly, IMR-32, and SK-N-BE(2).

| mTOR-inhibitor/ NB cell line | Dasatinib [μM] | Rapamycin [μM] | Dasatinib [DRF] | Rapamycin [DRF] |
|---|---|---|---|---|
| **Kelly** | 5.00 | 2.00 | 1.9 | 13.6 |
| **IMR-32** | 0.05 | 0.13 | 30.6 | 288.2 |
| **SK-N-BE(2)** | 20.00 | 5.00 | 1.3 | 4.9 |

**Table S3:** Viability tests to determine the dose reduction factor (DRF) of Dasatinib combined with Torin-2 in neuroblastoma (NB) cell line Kelly, IMR-32, and SK-N-BE(2).

| mTOR-inhibitor/ NB cell line | Dasatinib [μM] | Torin-2 [nM] | Dasatinib [DRF] | Torin-2 [DRF] |
|---|---|---|---|---|
| **Kelly** | 1.50 | 9.00 | 6.3 | 1.3 |
| **IMR-32** | 1.00 | 6.00 | 1.5 | 4.9 |
| **SK-N-BE(2)** | 12.50 | 15.00 | 2.1 | 1.9 |

**Table S4:** Viability test to determine half maximal inhibitory concentration ($IC_{50}$) of molecular-targeted inhibitors Rapamycin, Torin-2, and Dasatinib as well as chemotherapeutics Irinotecan (SN-38) and Temozolomide (TMZ) in neuroblastoma (NB) cell line Kelly and IMR-32.

| Inhibitor/ NB cell line | Rapamycin [µM] | Dasatinib [µM] | Torin-2 [nM] | SN-38 [nM] | TMZ [µM] |
|---|---|---|---|---|---|
| **Kelly** | 27.21 ± 0.006 | 9.47 ± 0.010 | 11.69 ± 0.019 | 2.74 ± 0.008 | 246.00 ± 0.004 |
| **IMR-32** | 37.47 ± 0.003 | 1.53 ± 0.057 | 29.67 ± 0.013 | 0.67 ± 0.009 | 159.90 ± 0.004 |

**Table S5:** Viability tests to determine the dose reduction factor (DRF) of Irinotecan (SN-38) combined with Temozolomide (TMZ) in neuroblastoma (NB) cell line Kelly and IMR-32.

| mTor-inhibitor/ NB cell line | SN-38 [nM] | TMZ [µM] | SN-38 [DRF] | TMZ [DRF] |
|---|---|---|---|---|
| **Kelly** | 1.00 | 225.00 | 2.7 | 1.1 |
| **IMR-32** | 0.40 | 120.00 | 0.2 | 1.3 |




**Fig. S4:** Viability tests to determine $IC_{50}$ of Irinotecan (SN-38) and Temozolomide (TMZ) in neuroblastoma cell line (A) Kelly and (B) IMR-32 after 72h treatment. The cell viability was tested by applying the MTT test as described under Methods.




(C)

| Inhibitor/ NB cell line | SN-38 + TMZ [CI] |
|---|---|
| **Kelly** | 1.20 ± 0.09 |
| **IMR-32** | 1.30 ± 0.15 |

**Note:** CI < 0.9 = synergistic; 0.9-1.1 = additive; > 1.1 = antagonistic

**Fig. S5:** Viability tests to determine $IC_{50}$ of chemotherapeutics Irinotecan (SN-38), Temozolomide (TMZ), and drug combination (SN-38/TMZ) in neuroblastoma (NB) cell line (A) Kelly and (B) IMR-32. Con: DMSO-treated control cells. (C) Viability tests to determine the combinatorial index (CI). The cell viability was tested by applying the MTT test as described under Methods.